The secondary endpoints that would carry the most weight - change in clinical status of subject at Day 14 and 28. Showing improvement progression details what leronlimab is doing. I do wish they had a day 7 in the mix. Secondary endpoints may sway the DSMC if primary is very close to stat sig, they may not. It would be nice to know who was on the DSMC. If they were frontline doctors I think they would be more inclined to push for an EUA.